TRAIL-based tumour therapy has been the subject of many publications in recent years, and two approaches can be distinguished: treatment with recombinant human TRAIL (rhTRAIL), and therefore, activation of TRAIL receptors (DR4, DR5) or induction of TRAIL up-regulation28. Here, TNFSF10 is linked to neoplasm.